Driehaus Capital Management LLC Dynavax Technologies Corp Transaction History

Driehaus Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$13.09 - $14.98 $220,658 - $252,517	-16,857 Reduced 1.04%	1,605,453 $22.4 Million
Q3 2023 Nov 14, 2023	BUY	$12.64 - $14.99 $7.11 Million - $8.43 Million	562,212 Added 53.03%	1,622,310 $24 Million
Q2 2023 Aug 14, 2023	SELL	$9.85 - $13.17 $509,727 - $681,534	-51,749 Reduced 4.65%	1,060,098 $13.7 Million
Q1 2023 May 15, 2023	SELL	$9.44 - $11.88 $484,659 - $609,931	-51,341 Reduced 4.41%	1,111,847 $10.9 Million
Q4 2022 Feb 14, 2023	BUY	$10.27 - $13.29 $4.55 Million - $5.88 Million	442,612 Added 61.42%	1,163,188 $12.4 Million
Q3 2022 Nov 14, 2022	BUY	$9.93 - $17.44 $7.16 Million - $12.6 Million	720,576 New	720,576 $7.52 Million
Q2 2022 Aug 15, 2022	SELL	$7.45 - $12.83 $3.53 Million - $6.09 Million	-474,327 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$9.75 - $14.44 $88,842 - $131,577	-9,112 Reduced 1.88%	474,327 $5.14 Million
Q4 2021 Feb 14, 2022	SELL	$13.17 - $20.94 $4.29 Million - $6.82 Million	-325,791 Reduced 40.26%	483,439 $6.8 Million
Q3 2021 Nov 15, 2021	BUY	$9.16 - $19.83 $7.41 Million - $16 Million	809,230 New	809,230 $15.5 Million

257

132M

371K

99.2K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.44B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Driehaus Capital Management LLC with notifications on news.